Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Masahiro TsuboiRoy S HerbstThomas JohnTerufumi KatoMargarita MajemChristian GrohéJie WangJonathan W GoldmanShun LuFilippo de MarinisFrances A ShepherdKi Hyeong LeeNhieu Thi LeArunee DechaphunkulDariusz KowalskiLaura BonannoManuel DómineLynne PooleAna BolanosYuri RukazenkovYi-Long WuPublished in: Targeted oncology (2024)
This is a summary of the original article ‟Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the epidermal growth factor receptor (EGFR) on cancer cells, causing cancer cell death and tumor shrinkage, and is an effective treatment for EGFR-mutated non-small cell lung cancer (NSCLC). The ADAURA study assessed the effects of osimertinib versus placebo in patients with EGFR-mutated (exon 19 deletion or L858R) early stage (IB-IIIA) NSCLC removed by surgery (resected). Previous results from ADAURA demonstrated that patients treated with osimertinib stayed alive and cancer-free (disease-free survival) significantly longer than patients who received placebo. Recent data showed the overall length of time patients were alive after starting treatment (overall survival). In both the primary stage II-IIIA and overall stage IB-IIIA populations, patients in the osimertinib group had a significant 51% reduction in the risk of death compared with the placebo group. The data demonstrated that osimertinib after surgery significantly improved overall survival in patients with resected, EGFR-mutated, stage IB-IIIA NSCLC.
Keyphrases
- epidermal growth factor receptor
- small cell lung cancer
- advanced non small cell lung cancer
- tyrosine kinase
- free survival
- prognostic factors
- end stage renal disease
- early stage
- brain metastases
- lymph node
- cell death
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- minimally invasive
- electronic health record
- squamous cell
- machine learning
- clinical trial
- wild type
- deep learning
- coronary artery bypass
- phase iii
- patient reported outcomes
- rectal cancer
- study protocol
- replacement therapy
- sentinel lymph node
- acute coronary syndrome
- coronary artery disease
- combination therapy
- placebo controlled
- percutaneous coronary intervention